Key Points
- Director Tommy Thompson bought 8,400 shares on Dec. 23 at an average price of $1.67 ($14,028 total), increasing his stake to 23,179 shares — a 56.84% rise; the trade was disclosed in an SEC Form 4 filing.
- TherapeuticsMD trades with a market cap of $19.44 million and a negative P/E (-168), a 52‑week range of $0.70–$2.44, and 50‑/200‑day moving averages of $1.55 and $1.27 respectively.
- Analyst and institutional signals lean negative: Weiss Ratings reaffirmed a Sell (d+) and MarketBeat shows an average "Sell", while Citadel Advisors increased its position by 125.5% in Q3; institutions own about 30.7% of the stock.
TherapeuticsMD, Inc. (NASDAQ:TXMD - Get Free Report) Director Tommy Thompson purchased 8,400 shares of TherapeuticsMD stock in a transaction that occurred on Tuesday, December 23rd. The shares were acquired at an average price of $1.67 per share, for a total transaction of $14,028.00. Following the acquisition, the director owned 23,179 shares in the company, valued at $38,708.93. This trade represents a 56.84% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
TherapeuticsMD Stock Performance
NASDAQ TXMD opened at $1.68 on Tuesday. The stock has a market cap of $19.44 million, a P/E ratio of -168.00 and a beta of 0.41. TherapeuticsMD, Inc. has a fifty-two week low of $0.70 and a fifty-two week high of $2.44. The stock has a 50 day simple moving average of $1.55 and a two-hundred day simple moving average of $1.27.
TherapeuticsMD (NASDAQ:TXMD - Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported $0.01 earnings per share (EPS) for the quarter. The firm had revenue of $0.78 million for the quarter. TherapeuticsMD had a return on equity of 0.27% and a net margin of 10.80%.
Analysts Set New Price Targets
Separately, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of TherapeuticsMD in a research report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of "Sell".
View Our Latest Research Report on TherapeuticsMD
Hedge Funds Weigh In On TherapeuticsMD
An institutional investor recently raised its position in TherapeuticsMD stock. Citadel Advisors LLC raised its position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD - Free Report) by 125.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 34,273 shares of the company's stock after buying an additional 19,073 shares during the quarter. Citadel Advisors LLC owned about 0.30% of TherapeuticsMD worth $36,000 at the end of the most recent quarter. 30.74% of the stock is owned by institutional investors and hedge funds.
TherapeuticsMD Company Profile
(
Get Free Report)
TherapeuticsMD, Inc (NASDAQ:TXMD) is a women's healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company's primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.
Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
